๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Unresectable Melanoma

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients NCT01638676Phase 1, Phase 21 site๐Ÿ“ Louisville University of Louisville ยท Tests: Vemurafenib, Metformin Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma NCT07627698Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System NCT07870265NA1 site๐Ÿ“ Brno Masaryk Memorial Cancer Institute ยท Tests: Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripherโ€ฆ Neoadjuvant Tebentafusp for Uveal Melanoma NCT06414590Phase 22 sites๐Ÿ“ Philadelphia๐Ÿ“ Philadelphia Thomas Jefferson University ยท Tests: Tebentafusp-Tebn Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. NCT05727904Phase 382 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Los Angeles Iovance Biotherapeutics, Inc. ยท Tests: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary NCT02828202n/a27 sites๐Ÿ“ Amiens๐Ÿ“ Annecy๐Ÿ“ Besanรงon Assistance Publique - Hรดpitaux de Paris ยท Tests: Biological, Tissular, Quality of life Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivoยฎ in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma NCT07221734Phase 319 sites๐Ÿ“ Funchal๐Ÿ“ Chernivtsi๐Ÿ“ Ivano-Frankivsk mAbxience Research S.L. ยท Tests: MB11 (Proposed Nivolumab Biosimilar), EU-Opdivoยฎ, US- sourced Opdivoยฎ A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy NCT06797297Phase 231 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Innovent Biologics (Suzhou) Co. Ltd. ยท Tests: IBI363, Pembrolizumab A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites๐Ÿ“ Sacramento๐Ÿ“ Celebration๐Ÿ“ Miami Marengo Therapeutics, Inc. ยท Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma NCT07223411n/a1 site๐Ÿ“ Pittsburgh John Kirkwood ยท Tests: Fianlimab + Cemiplimab, Relatlimab + Nivolumab Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients NCT06199713n/a1 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma NCT06594991Phase 212 sites๐Ÿ“ Los Angeles๐Ÿ“ Stanford๐Ÿ“ Hartford Memorial Sloan Kettering Cancer Center ยท Tests: Fianlimab, Cemiplimab, Ipilimumab A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-1607, Paclitaxel SUPRAME-ACTengineยฎ IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126Phase 371 sites๐Ÿ“ Phoenix๐Ÿ“ Scottsdale๐Ÿ“ Duarte Immatics US, Inc. ยท Tests: IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab ACTengineยฎ IMA203 Combined With mRNA-4203 NCT06946225Phase 14 sites๐Ÿ“ San Francisco๐Ÿ“ Boston๐Ÿ“ New York Immatics US, Inc. ยท Tests: IMA203, mRNA-4203 A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body NCT06413680Phase 1, Phase 211 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ North Haven Regeneron Pharmaceuticals ยท Tests: REGN10597, Cemiplimab AMT-253 in Patients With Advanced Solid Tumours NCT06209580Phase 1, Phase 21 site๐Ÿ“ Beijing Multitude Therapeutics Inc. ยท Tests: AMT-253 for injection Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma NCT05655312Phase 1, Phase 216 sites๐Ÿ“ Orange๐Ÿ“ Jacksonville๐Ÿ“ Miami Perspective Therapeutics ยท Tests: [203Pb]VMT01, [212Pb]VMT01, Nivolumab Duration of Anti-PD-1 Therapy in Metastatic Melanoma NCT02821013Phase 330 sites๐Ÿ“ Victoria๐Ÿ“ Coffs Harbour๐Ÿ“ Waratah Canadian Cancer Trials Group ยท Tests: Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment NCT04045691n/a59 sites๐Ÿ“ Graz๐Ÿ“ Innsbruck๐Ÿ“ Klagenfurt Pierre Fabre Pharma GmbH ยท Tests: Encorafenib, Binimetinib Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer NCT05896839Phase 1, Phase 226 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors NCT07280832Phase 1, Phase 21 site๐Ÿ“ Beijing Shanghai JMT-Bio Inc. ยท Tests: JMT108 Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021 NCT07302607n/a1 site๐Ÿ“ Strasbourg University Hospital, Strasbourg, France Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100Phase 21 site๐Ÿ“ San Francisco Kevin Kim, MD ยท Tests: Mirdametinib Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) NCT06246916Phase 3113 sites๐Ÿ“ Chandler๐Ÿ“ Gilbert๐Ÿ“ Tucson Regeneron Pharmaceuticals ยท Tests: fianlimab, cemiplimab, relatlimab+nivolumab High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies NCT05053555NA1 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: high dose rate brachytherapy, high dose rate brachytherapy A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma NCT06727630Phase 1, Phase 21 site๐Ÿ“ Beijing Zhuhai Yufan Biotechnologies Co., Ltd ยท Tests: PRJ1-3024
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy